Dienogest is a Small Molecule owned by Bayer, and is involved in 26 clinical trials, of which 24 were completed, and 2 are ongoing.

Dienogest acts as progesterone receptor agonist. Dienogest acts on endometriosis by reducing the endogenous production of oestradiol and thereby suppresses the trophic effects of estradiol on both the eutopic and ectopic endometrium. When given continuously, dienogest leads to a hypoestrogenic, hypergestagenic endocrine environment causing initial decidualization of endometrial tissue followed by atrophy of endometriotic lesions. Dienogest also exhibits therapeutic intervention for the treatment of dysmenorrhea due to increased progesterone receptor-binding affinity.

The revenue for Dienogest is expected to reach a total of $5.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Dienogest NPV Report.

Dienogest is currently owned by Bayer. Mochida Pharmaceutical is the other company associated in development or marketing of Dienogest.

Dienogest Overview

Dienogest (Visabelle/ Visan/ Visannette/ Allurene/ Visabelle/ Dinagest) is a progestogen preparation. It is formulated as tablets and film coated tablets for oral route of adminstration. Dienogest is indicated for the treatment of endometriosis, pelvic pain associated with endometriosis, pain associated with uterine adenomyosis. Dinagest is indicated for the treatment of functional dysmenorrhea.

Bayer Overview

Bayer is engaged in the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company’s product portfolio includes prescription products, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over the counter or OTC) products, seeds, crop protection solutions and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa and the Middle East. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, Germany.

The company reported revenues of (Euro) EUR44,081 million for the fiscal year ended December 2021 (FY2021), an increase of 6.5% over FY2020. The operating profit of the company was EUR3,353 million in FY2021, compared to an operating loss of EUR16,169 million in FY2020. The net profit of the company was EUR1,000 million in FY2021, compared to a net loss of EUR10,495 million in FY2020. The company reported revenues of EUR11,281 million for the third quarter ended September 2022, a decrease of 12% over the previous quarter.

Quick View – Dienogest

Report Segments
  • Innovator (NME)
Drug Name
  • Dienogest
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Women’s Health
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.